Dana-Farber Cancer Institute | Strategic Alliance Partners

November 05, 2025

Sara M. Tolaney, MD, MPH, discussed the use of T-DXd in patients with HER2-positive breast cancer with residual disease after neoadjuvant therapy.

November 04, 2025

The US FDA approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and older with relapsed or refractory AML with NPM1 gene mutations.

October 30, 2025

Experts highlight pivotal data in EGFR- and HER2-mutant NSCLC from the 2025 ESMO Congress, including updates on ADCs, TKIs, and real-world outcomes in LMD.

October 30, 2025

Paolo Tarantino, MD, PhD, discusses the clinical utility of data from the phase 3 neoCARHP trial in patients with HER2-positive early breast cancer.

October 28, 2025

Tarek Mouhieddine, MD, discusses future research directions with ferritin and ALC as biomarkers of response to bispecific antibodies in myeloma.

October 27, 2025

Joaquim Bellmunt, MD, PhD, discusses ways that ctDNA tests could augment bladder cancer management and the need for confirmatory data from ongoing trials.

October 26, 2025

The top 5 OncLive TV videos of the week cover insights in breast cancer and lung cancer.

October 24, 2025

Osimertinib plus chemotherapy resulted in a significant and improvement in OS in newly diagnosed EGFR-mutated advanced NSCLC vs osimertinib alone.

October 24, 2025

Joaquim Bellmunt, MD, PhD, discusses the rationale for and findings from the IMvigor011 trial of ctDNA-guided adjuvant atezolizumab vs placebo in MIBC.

October 23, 2025

Paolo Tarantino, MD, PhD, discusses key efficacy data with de-escalated THP with/without carboplatin in HER2-positive breast cancer.

October 21, 2025

Tarek Mouhieddine, MD, discusses data from a study of ferritin and ALC as biomarkers of response to bispecific antibodies in relapsed/refractory myeloma.

October 15, 2025

Alicia Morgans, MD, MPH, discusses the role of radioligand therapies for mCRPC and the importance of shared decision-making in prostate cancer management.

October 14, 2025

Alicia Morgans, MD, MPH, discusses data from the PEACE-3 trial that support the use of radium-223 plus enzalutamide in patients with mCRPC.

October 14, 2025

Tarek Mouhieddine, MD, discusses the use of ferritin and ALC as biomarkers of response to bispecific antibodies in relapsed/refractory multiple myeloma.

October 09, 2025

Paolo Tarantino, MD, PhD, discusses the design and background of the CompassHER2 pCR trial of THP in HER2-positive breast cancer.

October 09, 2025

Philip J. Kranzusch, PhD, was one of three scientists awarded top honors at the 2025 Blavatnik National Awards for Young Scientists.

October 07, 2025

Tarek Mouhieddine, MD, discusses the background and design of a study of correlates of response to bispecific antibodies in relapsed/refractory myeloma.

October 07, 2025

Proton therapy provides pediatric patients a treatment option that minimizes impact on long-term growth and development.

October 02, 2025

Five new faculty members have joined the Roswell Park Care Network, with St. Joseph’s Health in Syracuse to begin thoracic surgery services.

September 28, 2025

The top 5 OncLive TV videos of the week cover insights in solid tumors, breast cancer, pancreatic cancer, and multiple myeloma.